Resource Logo
NLM AIDSLINE

Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease.




 

Ann Neurol. 1988;23 Suppl:S82-7. Unique Identifier : AIDSLINE

3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus-associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.

Acquired Immunodeficiency Syndrome/CEREBROSPINAL FLUID/ *COMPLICATIONS Adult Aged Clinical Trials Dementia/CEREBROSPINAL FLUID/COMPLICATIONS/*DRUG THERAPY Human Male Middle Age Paraplegia/CEREBROSPINAL FLUID/COMPLICATIONS/*DRUG THERAPY Peripheral Nervous System Diseases/CEREBROSPINAL FLUID/ COMPLICATIONS/*DRUG THERAPY Thymidine/*ANALOGS & DERIVATIVES/PHARMACOKINETICS/THERAPEUTIC USE Time Factors CLINICAL TRIAL JOURNAL ARTICLE



 




Information in this article was accurate in June 30, 1988. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.